STOCK TITAN

Vaxcyte Inc - PCVX STOCK NEWS

Welcome to our dedicated news page for Vaxcyte (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vaxcyte's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vaxcyte's position in the market.

Rhea-AI Summary
Vaxcyte, Inc. (PCVX) completes enrollment in VAX-31 Adult Program Phase 1/2 study and expects topline safety, tolerability, and immunogenicity data in Q3 2024. Successful completion of VAX-24 Phase 2 Adult Program, moving towards Phase 3 readiness. Progress in VAX-24 Infant Phase 2 Study with expected data by Q1 2025. Significant advancements in global commercial manufacturing capacity. The company holds $1.2 billion in cash and investments as of December 31, 2023, with recent net proceeds of $816.5 million. Vaxcyte aims to advance either VAX-24 or VAX-31 into Phase 3 adult clinical program post VAX-31 study readout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.33%
Tags
earnings
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) will report Q4 and full-year 2023 financial results on Feb 27, 2024. A conference call and webcast will follow to discuss results and provide a business update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences earnings
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) closed its underwritten public offering of common stock, generating approximately $862.5 million in gross proceeds. The offering included over 12.6 million shares of common stock and pre-funded warrants to purchase additional shares, with joint book-running managers and lead managers overseeing the process. The company filed a shelf registration statement with the SEC, and the final prospectus supplement and accompanying prospectus are available on the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
offering
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) will participate in a fireside chat at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference in New York on February 8, 2024. The live webcast can be accessed through the Investors & Media section of the Company’s website. A replay will be available for approximately 30 days after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.34%
Tags
conferences
-
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) has announced the pricing of an underwritten public offering of common stock and pre-funded warrants, expecting to generate approximately $750.0 million in gross proceeds. The offering includes 10,937,500 shares of common stock and pre-funded warrants to purchase 781,250 shares of common stock, with a public offering price of $64.00 per share for common stock and $63.999 per pre-funded warrant. The underwriters have been granted a 30-day option to purchase up to an additional 1,757,812 shares of common stock at the public offering price per share. The offering is expected to close on February 2, 2024, subject to customary closing conditions. BofA Securities, Jefferies, Leerink Partners LLC, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering, with BTIG and Needham & Company as lead managers. Vaxcyte has filed a shelf registration statement with the SEC, and a preliminary prospectus supplement and accompanying prospectus have been filed. This press release does not constitute an offer to sell or a solicitation of an offer to buy these securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
offering
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) has initiated an underwritten public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase additional shares. BofA Securities, Jefferies, Leerink Partners, Evercore ISI, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering. The company filed a shelf registration statement with the SEC, and a preliminary prospectus supplement will be available on the SEC's website. This press release does not constitute an offer to sell or a solicitation to buy these securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.04%
Tags
offering
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) completes enrollment in Phase 1/2 study for VAX-31, a potential best-in-class pneumococcal conjugate vaccine franchise, with topline safety, tolerability, and immunogenicity data expected in Q3 2024. VAX-31 aims to provide coverage for 95% of IPD circulating in the U.S. adult population, addressing a significant public health need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
clinical trial
-
Rhea-AI Summary
Vaxcyte, Inc. (Nasdaq: PCVX) appoints Whitney Jones as Chief People Officer to lead human resources strategy and operations, emphasizing a people-first approach to support organizational growth strategies and advance vaccine candidates, including lead pneumococcal conjugate vaccine franchise programs, VAX-24 and VAX-31.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.81%
Tags
management
-
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Study, Plans for Phase 3 Pivotal Study and Receives Encouraging Input on CMC Licensure Requirements; Enrollment in VAX-24 Infant Phase 2 Study Progressing
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.07%
Tags
none
Rhea-AI Summary
Vaxcyte, Inc. (PCVX) published results from the VAX-24 Phase 1/2 clinical proof-of-concept study in The Lancet Infectious Diseases. The study demonstrated that VAX-24 had a safety and tolerability profile similar to Prevnar 20® (PCV20) at all doses studied and met or exceeded regulatory immunogenicity standards for all 24 serotypes at the conventional 2.2 mcg dose. The company plans to advance the VAX-24 2.2 mcg dose into a Phase 3 program, with topline data expected in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
clinical trial
Vaxcyte Inc

Nasdaq:PCVX

PCVX Rankings

PCVX Stock Data

7.73B
99.23M
0.78%
96.55%
9.88%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Foster City

About PCVX

sutrovax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. sutrovax’s lead product candidate is a pneumococcal conjugate vaccine (pcv) that is designed to prevent invasive pneumococcal disease (ipd) caused by streptococcus pneumoniae. sutrovax’s broad-spectrum pcv is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults. the current mainstay vaccine only covers approximately 40% of the circulating strains causing ipd yet generates $6b in annual sales. sutrovax has generated positive pre-clinical proof-of-concept with its significantly broader-spectrum pcv compared head-to-head to current vaccines using well accepted immunological endpoints. in addition to its lead pcv product candidate, the company also has a promising early-stage pipeline addressing othe